Antiangiogenic Effect of Ethanol Extract of <i>Vigna angularis</i> via Inhibition of Phosphorylation of VEGFR2, Erk, and Akt

Kwon, Oh Sung; Jeong, Myoung Seok; Kim, Bonglee; Kim, Sung-Hoon

doi:https://doi.org/10.1155/2015/371368

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Introduction Materials and Methods Results Discussion References Copyright Related Articles

Research Article | Open Access

Volume 2015 | Article ID 371368 | https://doi.org/10.1155/2015/371368

Antiangiogenic Effect of Ethanol Extract of Vigna angularis via Inhibition of Phosphorylation of VEGFR2, Erk, and Akt

Oh Sung Kwon,¹Myoung Seok Jeong,²Bonglee Kim,²and Sung-Hoon Kim²

Academic Editor: Shun-Wan Chan

Received19 Jun 2015

Revised03 Aug 2015

Accepted04 Aug 2015

Published19 Aug 2015

Abstract

Though dietary azuki bean (Vigna angularis) seed containing antioxidant proanthocyanidins was known to have multibiological activities including antioxidant, hypotensive, anti-inflammatory, and immunomodulatory activities, the antiangiogenic activity of ethanol extract of Vigna angularis (EVA) was never reported so far. In the present study, the antiangiogenic mechanism of EVA was examined in human umbilical vein endothelial cells (HUVECs). EVA showed weak cytotoxicity in HUVECs, while it significantly suppressed the VEGF induced proliferation of HUVECs. Consistently, wound healing assay revealed that EVA inhibited the VEGF induced migration of HUVECs. Also, EVA abrogated the VEGF induced tube formation of HUVECs in a concentration dependent fashion. Furthermore, Matrigel plug assay showed that EVA significantly reduced the hemoglobin level of Matrigel plug in mice compared to untreated control. Of note, EVA effectively attenuated the phosphorylation of VEGFR2, Erk, and Akt in VEGF-treated HUVECs. Overall, our findings suggest that EVA inhibits angiogenesis in VEGF-treated HUVECs via inhibition of phosphorylation of VEGFR2, ERK, and Akt.

1. Introduction

Angiogenesis is well known as a phenomenon that makes new blood vessels from the preexisting vasculature [1]. The aberrant angiogenesis has role in a variety of diseases such as cancer [2, 3], psoriasis [4], arthritis [5], obesity [6], endometriosis [7], atherosclerosis [8], hypertension [9], diabetic retinopathy [10], and age-related macular degeneration [11]. Many of angiogenesis inhibitors have been developed for cancer treatment and prevention [12, 13], since Judah Folkman first claimed the critical role of angiogenesis for tumor growth [14].

Vascular endothelial growth factor (VEGF) binds to VEGF receptors (VEGFR), VEGFR1, VEGFR2, and VEGFR3, during angiogenesis [15]. Among these, VEGFR2 (KDR/Flk-1) has most important role in angiogenesis, including transduction of angiogenic signals after binding VEGF [16]. VEGFR2 became dimerized after the binding [17], promoting the activation of extracellular signal-regulated kinases (ERKs), phosphatidylinositol 3-kinase (PI3K), and Akt [18–20].

Recently angiogenesis inhibitors [21–24] from natural products are attractive, though not powerful, with less side effects such as fetal development, bleeding, blood clot, hypertension, and protein in urine [25, 26]. Our team also reported potent antiangiogenic materials from natural products, such as STB-HO [27], beta-sitosterol [28], cryptotanshinone [29], and emodin [30].

Vigna angularis that has been usually used as dietary azuki bean was known to have antioxidative [31], hepatoprotective [32], antimicrobial [33], osteogenic [34], anti-inflammatory [9, 35], hypotensive [36, 37], antimetastatic [38], and immunomodulatory [39] activities. Until now, there is no evidence on the antiangiogenic activity of Vigna angularis. We studied the antiangiogenic mechanism of ethanol extract of Vigna angularis (EVA) in VEGF-treated human umbilical vein endothelial cells (HUVECs) using cytotoxicity assay, proliferation assay, wound healing migration assay, tube formation assay, Matrigel plug assay, and Western blotting.

2. Materials and Methods

2.1. Preparation of Ethanol Extract of Vigna angularis

Azuki bean (Vigna angularis) was purchased from Hanil Herbal Company (Seoul, Republic of Korea), identified by Professor Namin Baek, Kyung Hee University, and stored at Cancer Preventive Material Development Research Center (CPMDRC), Kyung Hee University, Republic of Korea, with voucher specimen number (2012-05-07). Azuki bean (600 g) was socked in 95% ethanol for one week at room temperature. The EtOH solution was then filtered, evaporated under reduced pressure, and lyophilized to obtain 14.87 g of ethanol extract of Vigna angularis (EVA yield = 2.47%). The extract was dissolved in DMSO.

2.2. Cell Culture

Human umbilical vein endothelial cells (HUVECs, passages between 4 and 6) were obtained from fresh human umbilical cord veins after collagenase treatment as described previously [22, 40]. The cells were maintained in M199 (Invitrogen, Carlsbad, CA) with 20% fetal bovine serum (FBS), 5 U/mL heparin and 3 ng/mL basic fibroblast growth factor (R&D Systems, Minneapolis, MN), and 100 U/mL of antibiotic-antimycotic in 0.1% gelatin coated flasks. The cells were cultured at 37°C in a humidified atmosphere containing 5% CO₂.

2.3. Cytotoxicity Assay

Cytotoxicity induced by EVA was evaluated in HUVECs by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. The cells were seeded onto microplates (1 10⁴ cells/well) and treated with 0, 10, 20, 30, 40, and 50 g/mL of EVA for 48 h. The cells were treated with MTT solution (1 mg/mL) for 2 h. DMSO was added to cells for 2 h. Optical density (OD) of the solution was measured using a microplate reader (Molecular Devices Co., Sunnyvale, CA) at 570 nm. Cell viability was calculated as a percentage of viable cells in EVA-treated group versus untreated control by the following equation. Cell viability (%) = [OD (EVA) − OD (Blank)]/[OD (Control) − OD (Blank)] 100.

2.4. Proliferation Assay

Cell proliferation was determined using a 5-bromo-2′-deoxyuridine (BrdU) colorimetric assay kit (Roche, Mannheim, Germany). Briefly, HUVECs (5 10³ cells/well) were seeded into 0.1% gelatin coated microplates and incubated in a humidified atmosphere containing 5% CO₂ at 37°C. After starvation for 6 h in M199 containing 5% heat-inactivated FBS, the cells were treated with various concentrations of EVA (10, 20, and 30 μg/mL) in the presence or absence of VEGF (50 ng/mL) and incubated at 37°C for 48 h. 10 μL of BrdU (100 μg/mL) was added; the cells were incubated at 37°C for 6 h. The cells were fixed with anti-BrdU and measured by the substrate reaction. 25 μL of 1 M H₂SO₄ was added to stop the reaction and the absorbance was calculated by using an ELISA reader (Molecular Devices Co., USA) (450 nm with 690 nm correction).

2.5. Wound Healing Migration Assay

The migratory activity of HUVECs was tested by a wound healing assay. The cells (4 10⁵ cells/2 mL) were exposed to various concentrations of EVA (10 and 20 μg/mL) in a 6-well plate in the presence or absence of VEGF (50 ng/mL) and incubated in a humidified atmosphere containing 5% CO₂ at 37°C. The plates were scratched with a 200 μL pipet tip and washed with PBS for 3 times. Then, cells were treated with EVA extracts (0, 10, and 20 μg/mL) in media. The cells were fixed and stained with Diff-Quick after 24 h, and randomly chosen fields were photographed with a fluorescence microscope (AXIO observer A1, Zeiss, Germany). The migrated cells were calculated.

2.6. Tube Formation Assay

Tube formation assay was conducted as described previously [41]. 250 μL of Matrigel (Becton Dickinson Labware, Bedford, MA) was added to 24-well plates and incubated at 37°C for 1 h. HUVECs (1 10⁵ cells/well) were treated with EVA (0, 10, and 20 μg/mL) in the presence or absence of VEGF (50 ng/mL). And cells were treated with LY294002 (20 μM), PD98059 (50 μM), EVA (20 μg/mL), and VEGF (50 ng/mL). Randomly chosen fields were photographed with Axiovert S 100 light microscope (Carl Zeiss, USA) at 100x magnification after 18 h. Tube network was measured by using NIH Scion image program.

2.7. Matrigel Plug Assay

Six-week-old C57BL/6 mice (Chungang animal expt. Co., Seoul, Republic of Korea) were given subcutaneous injection of 0.5 mL of growth factor reduced Matrigel containing VEGF (50 ng/mL) and heparin (10 U/mL). EVA extracts (40 μg/mL in PBS) were orally administrated (300 μg/kg) after 7 days of Matrigel injection (three mice per group). Ten days later, the mice were sacrificed, and the matrigel plugs were detached. To indirectly quantify the formation of new blood vessel, the amount of hemoglobin (Hb) was calculated using the hemoglobin assay kit (YD Diagnostics, Republic of Korea). The concentration of Hb was measured from standard curve made from the known amount of Hb provided according to the manufacturer’s protocol.

2.8. Western Blotting

After treatment of EVA (0, 10, or 20 μg/mL) in a presence of VEGF (50 ng/mL), HUVECs were lysed with RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholic acid, 1 M EDTA, 1 mM Na₃VO₄, 1 mM NaF, and protease inhibitors cocktail, pH 7.4). Samples were quantified by using a Bio-Rad DC protein assay kit II (Bio-Rad, Hercules, CA, USA), separated by electrophoresis on 8 to 15% SDS-PAGE gel and electrotransferred onto a Hybond ECL transfer membrane (Amersham Pharmacia, Piscataway, NJ, USA). After blocking with 3–5% nonfat skim milk, the membrane was incubated with antibodies for p-Akt, Akt, VEGFR2 (FLK1), p-Erk, and Erk (Cell Signaling Technology, Danvers, MA) and -actin (Sigma Aldrich Co., St. Louis, MO). Blots were exposed to horseradish peroxidase- (HRP-) conjugated secondary anti-mouse or rabbit antibodies (AbDserotec, kidlington, UK). Protein expression was measured by using enhanced chemiluminescence (ECL) system (Amersham Pharmacia, Piscataway, NJ, USA).

2.9. Statistical Analyses

All data were expressed as mean SD (standard deviation). The statistically significant differences between untreated control and EVA-treated cells were calculated by ANOVA test followed by a post hoc analysis (Tukey - or Dunnettes multiple comparison test) using Prism software 5 (GraphPad Software, Inc., San Diego, CA, USA).

3. Results

3.1. EVA Shows Weak Cytotoxicity in HUVECs and Suppressed VEGF Induced Proliferation of HUVECs

Cytotoxicity of EVA was evaluated in HUVECs using MTT assay. As shown in Figure 1, EVA decreased the viability of HUVECs to ~60% at the concentration of 50 µM for 48 h. EVA treatment showed cytotoxicity in VEGF-treated HUVECs in a concentration dependent manner (Figure 2).

3.2. EVA Significantly Inhibits the VEGF Induced Migration and Tube Formation in HUVECs

It was well known that endothelial cells migrate in tandem using adhesion molecules such as integrins and form loops to become a full-fledged vessel lumen like tube formation [42]. To check the physiological angiogenic formation, wound healing assay and tube formation assay were carried out in HUVECs.

As shown in Figures 3(a) and 3(b), EVA significantly reduced the number of tube forming endothelial cells, whereas tube-like formation by endothelial cells was enhanced by VEGF in HUVECs. Similarly, EVA significantly suppressed the VEGF induced migratory activity of HUVECs, while the gap physically made by tip was narrowed via repair through migratory activity of VEGF-treated HUVECs (Figures 4(a) and 4(b)).

(a)

(b)

Figure 3

EVA abrogates VEGF induced tube formation in HUVECs. (a) Matrigel (250 μL) was added to 24-well plates and allowed to solidify for 1 h at 37°C. HUVECs (1 10⁵ cells/well) were treated with 10 and 20 μg/mL of EVA in the presence or absence of VEGF (50 ng/mL) and incubated at 37°C. After 18 h, randomly chosen fields were photographed under an Axiovert S 100 light microscope. (b) Bar graph represents the quantification of tube formation of untreated control or VEGF-treated control and EVA-treated groups. Data are presented as means ± SD. versus VEGF-treated group.

(a)

(b)

Figure 4

EVA suppresses VEGF induced migration in HUVECs by wound healing assay. (a) The cells (4 10⁵ cells/2 mL) were treated with 0, 10, and 20 μg/mL of EVA in a 6-well plate in the presence of VEGF (50 ng/mL) and incubated at 37°C. The number of cells migrated into the scratched area was calculated. (b) Bar graph represents the quantification of migrated cells of untreated control or VEGF-treated control and EVA-treated groups. Data are presented as means ± SD. versus VEGF only treated group.

3.3. EVA Significantly Reduces Hemoglobin Content in VEGF Induced Angiogenesis of Matrigel Plugs of C57BL/6 Mice

To confirm the antiangiogenic activity of EVA, Matrigel plug assay was carried out. EVA (300 μg/kg) extract was administered orally to C57BL/6 mice for 7 days before growth factor reduced Matrigel was subcutaneously injected into right flank of mice. As shown in Figures 5(a) and 5(b), EVA significantly reduced hemoglobin content in VEGF induced angiogenesis of Matrigel plugs of C57BL/6 mice, while dark red color was shown in Matrigel plugs of untreated control group.

(a)

(b)

Figure 5

EVA significantly reduces hemoglobin content in VEGF induced angiogenesis in Matrigel plugs of mice. Six-week-old C57BL/6 mice were given EVA (300 μg/kg) extracts via oral administration for 7 days before growth factor reduced Matrigel with VEGF (25 ng) and heparin (5 U) was subcutaneously injected into right flank of C57BL/6. Ten days later, Matrigel plugs were removed. (a) The amount of hemoglobin (Hb) was measured using the hemoglobin assay kit. ((A), (B), and (C) represent negative control, positive control, and EVA-treated group, resp.) (b) Bar graph represents the quantification of Hb concentration from each of groups. Data are presented as means ± SD. versus positive control group.

3.4. EVA Effectively Attenuates the Phosphorylation of VEGFR2, Erk, and Akt in VEGF-Treated HUVECs

Since Dr. Judah Folkman suggested the importance of tumor angiogenesis, a variety of angiogenesis related factors such as VEGF, bFGF, PDGF, angiopoietin, and transforming growth factor-β (TGF-β) were studied for years [1, 43]. To elucidate antiangiogenic molecular mechanism of EVA, Western blot analysis was performed in VEGF-treated HUVECs. As shown in Figure 6, EVA effectively attenuated the phosphorylation of VEGFR2 and Erk and Akt in VEGF-treated HUVECs.

(a)

(b)

3.5. Akt, Erk Inhibitors, and EVA Attenuate Tube Formation Enhanced by VEGF in HUVECs

To investigate the roles of Erk and Akt in angiogenesis, tube formation assay was conducted with HUVECs in the presence of LY294002 (Akt inhibitor) or PD98059 (Erk inhibitor). As shown in Figures 7(a) and 7(b), Akt, Erk inhibitors, and EVA treatments inhibited tube formation enhanced by VEGF. Particularly, LY294002 and EVA significantly attenuated the tube formation.

(a)

(b)

Figure 7

Akt, Erk inhibitors, and EVA attenuate tube formation enhanced by VEGF in HUVECs. (a) Matrigel (250 μL) was added to 24-well plates and EVA (20 μg/mL), LY294002 (Akt inhibitor, 20 μM), and PD98059 (Erk inhibitor, 50 μM) were treated to HUVECs (1 10⁵ cells/well) in the presence of VEGF (50 ng/mL) and incubated at 37°C. After 18 h, randomly chosen fields were photographed under an Axiovert S 100 light microscope. (b) Bar graph represents the quantification of tube formation of each group. Data are presented as means ± SD. versus VEGF-treated group.

4. Discussion

Azuki bean (Vigna angularis) has been used in east Asian food, and its coat of seed was known to contain water-soluble anthocyanins, catechins, and flavonols [44]. Despite multibiological activities of azuki bean, its antiangiogenic activity was never reported until now. So, this study elucidates the antiangiogenic mechanism of azuki bean in VEGF-treated HUVECs.

Though EVA exerted weak cytotoxicity in HUVECs, EVA significantly suppressed the VEGF induced proliferation of HUVECs at nontoxic concentrations, implying that EVA has antiangiogenic potential by blocking pathological angiogenic process via VEGF induced proliferation of endothelial cells, since these endothelial cells become motile and invasive and protrude filopodia, which drives new vessel formation [14, 25, 42].

Also, EVA inhibited VEGF induced migration of HUVECs in wound healing assay and suppressed VEGF induced tube formation of HUVECs in a concentration dependent manner in tube formation assay, strongly indicating that EVA could inhibit the motility and tube formation of proliferative endothelial cells.

To confirm in vivo antiangiogenic activity of EVA, Matrigel plug assay was performed in C57BL6 mice orally administered by EVA extracts for 1 week earlier. Here, we observed less red color in Matrigel plugs isolated from mice treated by EVA, while black red color was shown in those of untreated control group. The treatment of EVA significantly reduced the hemoglobin level of Matrigel plug in mice compared to untreated control, demonstrating antiangiogenic activity of EVA. However, it requires further in vivo angiogenesis studies using Matrigel plug assay via direct EVA treatment in the increased number of mice or CAM assay in the near future.

It was well documented that several molecules were involved in angiogenesis process. Angiogenesis is processed via the interaction of the VEGF family of proangiogenic cytokines and their receptors. The VEGF family includes VEGFA, VEGFB, VEGFC, VEGFD, VEGFE, and placental growth factor (PGF) with three receptors including VEGFR1 (Fms-like tyrosine kinase 1/Flt-1), VEGFR2 (Flk-1/KDR), and VEGFR3 (Flt-4) [20, 45, 46]. Also, VEGFR2 expression is typically limited to vessel endothelial cells, whereas VEGFR1 can be usually found in bone-marrow derived progenitors [47]. Furthermore, there was evidence that Akt and Erk mediate angiogenesis in endothelial cells [48–53]. sc-221226, an Akt inhibitor, attenuated sphingosine-1-phosphate induced angiogenesis in endothelial progenitor cells [54]. Also, low molecular weight fucoidan inhibited angiogenesis in vitro and in vivo evidenced by attenuation of tube formation of hypoxic HUVECs and suppressing Akt activity reduced hypoxia-induced VEGF secretion in T24 cells, supporting the involvement of Akt in the induction of HIF-1α and VEGF and angiogenesis [55]. Epidermal growth factor-like domain 7 promotes angiogenesis via ERK signaling pathway in endothelial cells [56]. And fractalkine, a large cytokine protein of 373 amino acids, stimulates angiogenesis by activation of ERK and Akt [57]. These results support our conclusions. The result of Western blotting revealed that EVA effectively attenuated the phosphorylation of VEGFR2, Erk, and Akt in VEGF-treated HUVECs, implying that EVA inhibited angiogenesis in VEGF-treated HUVECs via suppression of VEGFR2, Akt, and Erk. Also, LY294002 (Akt inhibitor) showed similar effect on VEGF-enhanced tube formation, indicating that inhibitory effect of EVA on angiogenesis in HUVECs could be by inhibition of Akt. In addition, azuki bean was reported to contain four furanylmethyl glycosides, angularides A–D, one ent-kaurane diterpene glycoside, angularin A, and four triterpenoid saponins, angulasaponins A–D, cyanidin and (+)-catechin, proanthocyanidins, digalactosyl ononitol, and gibberellin 2-oxidases [36, 44, 58–60]. Among them, anthocyanidin was well known to exert antiangiogenic activity in endothelial cells [61, 62].

In summary, EVA significantly suppressed the VEGF induced proliferation, migration, tube formation, and angiogenesis in HUVECs, and the molecular mechanism is the phosphorylation inhibition of VEGFR2 and Erk and Akt in VEGF-treated HUVECs. Overall, our findings suggest that EVA inhibits angiogenesis in VEGF-treated HUVECs via phosphorylation inhibition of VEGFR2 and Erk and Akt. Our study suggests that EVA is a promising natural agent which has antiangiogenic activity in HUVECs. However, further study is required to find out a leading antiangiogenic constituent from EVA and its potency for clinical application as a functional food.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Oh Sung Kwon, Myoung Seok Jeong, and Bonglee Kim are co-first authors.

Acknowledgment

This work was supported by The Korea Science and Engineering Foundation (KOSEF) grant funded by the Korean government (MEST) (nos. 2011-0006220 and 0013640).

References

J. Folkman and M. Klagsbrun, “Angiogenic factors,” Science, vol. 235, no. 4787, pp. 442–447, 1987.
View at: Publisher Site | Google Scholar
H.-J. Lee, N.-J. Seo, S.-J. Jeong et al., “Oral administration of penta-O-galloyl-beta-d-glucose suppresses triple-negative breast cancer xenograft growth and metastasis in strong association with JAK1-STAT3 inhibition,” Carcinogenesis, vol. 32, no. 6, pp. 804–811, 2011.
View at: Publisher Site | Google Scholar
A. Bikfalvi, “Tumor angiogenesis,” Bulletin du Cancer, vol. 94, no. 7, supplement, pp. F193–F198, 2007.
View at: Publisher Site | Google Scholar
A. K. Weidemann, A. A. Crawshaw, E. Byrne, and H. S. Young, “Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis,” Clinical, Cosmetic and Investigational Dermatology, vol. 6, pp. 233–244, 2013.
View at: Publisher Site | Google Scholar
X. Kong, Y. Zhang, C. Liu et al., “Anti-angiogenic effect of triptolide in rheumatoid arthritis by targeting angiogenic cascade,” PLoS ONE, vol. 8, no. 10, Article ID e77513, 2013.
View at: Publisher Site | Google Scholar
A. A. Joharapurkar, N. A. Dhanesha, and M. R. Jain, “Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 7, pp. 73–84, 2014.
View at: Publisher Site | Google Scholar
D. Djokovic and C. Calhaz-Jorge, “Angiogenesis as a therapeutic target in endometriosis,” Acta Medica Portuguesa, vol. 27, no. 4, pp. 489–497, 2014.
View at: Google Scholar
K. Demuth, I. Myara, and N. Moatti, “Biology of the endothelial cell and atherogenesis,” Annales de Biologie Clinique, vol. 53, no. 4, pp. 171–191, 1995.
View at: Google Scholar
Y. Mukai and S. Sato, “Polyphenol-containing azuki bean (Vigna angularis) seed coats attenuate vascular oxidative stress and inflammation in spontaneously hypertensive rats,” Journal of Nutritional Biochemistry, vol. 22, no. 1, pp. 16–21, 2011.
View at: Publisher Site | Google Scholar
Y. Yang, K. Yang, Y. Li et al., “Decursin inhibited proliferation and angiogenesis of endothelial cells to suppress diabetic retinopathy via VEGFR2,” Molecular and Cellular Endocrinology, vol. 378, no. 1-2, pp. 46–52, 2013.
View at: Publisher Site | Google Scholar
H. Wang, J. Guo, X. Z. West et al., “Detection and biological activities of carboxyethylpyrrole ethanolamine phospholipids (CEP-EPs),” Chemical Research in Toxicology, vol. 27, no. 12, pp. 2015–2022, 2014.
View at: Publisher Site | Google Scholar
B. Al-Husein, M. Abdalla, M. Trepte, D. L. DeRemer, and P. R. Somanath, “Antiangiogenic therapy for cancer: an update,” Pharmacotherapy, vol. 32, no. 12, pp. 1095–1111, 2012.
View at: Publisher Site | Google Scholar
C. A. Staton, N. J. Brown, and M. W. R. Reed, “Current status and future prospects for anti-angiogenic therapies in cancer,” Expert Opinion on Drug Discovery, vol. 4, no. 9, pp. 961–979, 2009.
View at: Publisher Site | Google Scholar
J. Folkman, “What is the role of endothelial cells in angiogenesis?” Laboratory Investigation, vol. 51, no. 6, pp. 601–604, 1984.
View at: Google Scholar
H. J. Cui, A. L. Yang, H. J. Zhou et al., “Buyang huanwu decoction promotes angiogenesis via vascular endothelial growth factor receptor-2 activation through the PI3K/Akt pathway in a mouse model of intracerebral hemorrhage,” BMC Complementary and Alternative Medicine, vol. 15, p. 91, 2015.
View at: Publisher Site | Google Scholar
M. Shibuya and L. Claesson-Welsh, “Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis,” Experimental Cell Research, vol. 312, no. 5, pp. 549–560, 2006.
View at: Publisher Site | Google Scholar
R. Roskoski Jr., “VEGF receptor protein-tyrosine kinases: structure and regulation,” Biochemical and Biophysical Research Communications, vol. 375, no. 3, pp. 287–291, 2008.
View at: Publisher Site | Google Scholar
I. Zachary and G. Gliki, “Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family,” Cardiovascular Research, vol. 49, no. 3, pp. 568–581, 2001.
View at: Publisher Site | Google Scholar
L. Claesson-Welsh and M. Welsh, “VEGFA and tumour angiogenesis,” Journal of Internal Medicine, vol. 273, no. 2, pp. 114–127, 2013.
View at: Publisher Site | Google Scholar
N. Ferrara, H.-P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003.
View at: Publisher Site | Google Scholar
T. P. Hamsa and G. Kuttan, “Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators,” Drug and Chemical Toxicology, vol. 35, no. 1, pp. 57–70, 2012.
View at: Publisher Site | Google Scholar
J.-E. Huh, E.-O. Lee, M.-S. Kim et al., “Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways,” Carcinogenesis, vol. 26, no. 8, pp. 1436–1445, 2005.
View at: Publisher Site | Google Scholar
L.-L. Wang, J.-J. Li, Z.-B. Zheng, H.-Y. Liu, G.-J. Du, and S. Li, “Antitumor activities of a novel indolin-2-ketone compound, Z24: more potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells,” European Journal of Pharmacology, vol. 502, no. 1-2, pp. 1–10, 2004.
View at: Publisher Site | Google Scholar
F. Zhang, Z. Zhang, L. Chen et al., “Curcumin attenuates angiogenesis in liver fibrosis and inhibits angiogenic properties of hepatic stellate cells,” Journal of Cellular and Molecular Medicine, vol. 18, no. 7, pp. 1392–1406, 2014.
View at: Publisher Site | Google Scholar
R. J. Young and M. W. R. Reed, “Anti-angiogenic therapy: concept to clinic,” Microcirculation, vol. 19, no. 2, pp. 115–125, 2012.
View at: Publisher Site | Google Scholar
L. S. Wood, “Management of vascular endothelial growth factor and multikinase inhibitor side effects,” Clinical Journal of Oncology Nursing, vol. 13, no. 6, pp. 13–18, 2009.
View at: Publisher Site | Google Scholar
S.-Y. Cho, H.-J. Lee, S.-M. Cho, B. Kim, Y. K. Jung, and S.-H. Kim, “Particled Mica, STB-HO has chemopreventive potential via G1 arrest, and inhibition of proliferation and vascular endothelial growth factor receptor 2 in HCT colorectal cancer cells,” BMC Complementary and Alternative Medicine, vol. 13, article 189, 2013.
View at: Publisher Site | Google Scholar
S. H. Sook, H.-J. Lee, J.-H. Kim et al., “Reactive oxygen species-mediated activation of AMP-activated protein kinase and c-jun N-terminal kinase plays a critical role in beta-sitosterol-induced apoptosis in multiple myeloma U266 cells,” Phytotherapy Research, vol. 28, no. 3, pp. 387–394, 2014.
View at: Publisher Site | Google Scholar
H.-J. Lee, D.-B. Jung, E. J. Sohn et al., “Inhibition of hypoxia inducible factor alpha and astrocyte-elevated gene-1 mediates cryptotanshinone exerted antitumor activity in hypoxic PC-3 cells,” Evidence-based Complementary and Alternative Medicine, vol. 2012, Article ID 390957, 13 pages, 2012.
View at: Publisher Site | Google Scholar
M.-K. Ha, Y. H. Song, S.-J. Jeong et al., “Emodin inhibits proinflammatory responses and inactivates histone deacetylase 1 in hypoxic rheumatoid synoviocytes,” Biological and Pharmaceutical Bulletin, vol. 34, no. 9, pp. 1432–1437, 2011.
View at: Publisher Site | Google Scholar
Y. Yao, X. Cheng, S. Wang, L. Wang, and G. Ren, “Influence of altitudinal variation on the antioxidant and antidiabetic potential of azuki bean (Vigna angularis),” International Journal of Food Sciences and Nutrition, vol. 63, no. 1, pp. 117–124, 2012.
View at: Publisher Site | Google Scholar
K.-H. Han, M. Fukushima, K. Ohba et al., “Hepatoprotective effects of the water extract from adzuki bean hulls on acetaminophen-induced damage in rat liver,” Journal of Nutritional Science and Vitaminology, vol. 50, no. 5, pp. 380–383, 2004.
View at: Publisher Site | Google Scholar
Y. Hori, S. Sato, and A. Hatai, “Antibacterial activity of plant extracts from azuki beans (Vigna angularis) in vitro,” Phytotherapy Research, vol. 20, no. 2, pp. 162–164, 2006.
View at: Publisher Site | Google Scholar
T. Itoh, M. Nakamura, H. Nakamichi, M. Ando, Y. Tsukamasa, and Y. Furuichi, “Regulation of the differentiation of osteoblasts and osteoclasts by a hot-water extract of adzuki beans (Vigna angularis),” Bioscience, Biotechnology, and Biochemistry, vol. 78, no. 1, pp. 92–99, 2014.
View at: Publisher Site | Google Scholar
Y. Jiang, K.-W. Zeng, B. David, and G. Massiot, “Constituents of Vigna angularis and their in vitro anti-inflammatory activity,” Phytochemistry, vol. 107, pp. 111–118, 2014.
View at: Publisher Site | Google Scholar
Y. Mukai and S. Sato, “Polyphenol-containing azuki bean (Vigna angularis) extract attenuates blood pressure elevation and modulates nitric oxide synthase and caveolin-1 expressions in rats with hypertension,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 19, no. 7, pp. 491–497, 2009.
View at: Publisher Site | Google Scholar
S. Sato, Y. Mukai, J. Yamate et al., “Effect of polyphenol-containing azuki bean (Vigna angularis) extract on blood pressure elevation and macrophage infiltration in the heart and kidney of spontaneously hypertensive rats,” Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 1, pp. 43–49, 2008.
View at: Publisher Site | Google Scholar
T. Itoh, H. Umekawa, and Y. Furuichi, “Potential ability of hot water adzuki (Vigna angularis) extracts to inhibit the adhesion, invasion, and metastasis of murine B16 melanoma cells,” Bioscience, Biotechnology and Biochemistry, vol. 69, no. 3, pp. 448–454, 2005.
View at: Publisher Site | Google Scholar
H.-H. Kim, S.-W. Kim, D.-S. Kim, H.-M. Oh, M.-C. Rho, and S.-H. Kim, “Vigna angularis inhibits mast cell-mediated allergic inflammation,” International Journal of Molecular Medicine, vol. 32, no. 3, pp. 736–742, 2013.
View at: Publisher Site | Google Scholar
E. A. Jaffe, R. L. Nachman, C. G. Becker, and C. R. Minick, “Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria,” The Journal of Clinical Investigation, vol. 52, no. 11, pp. 2745–2756, 1973.
View at: Publisher Site | Google Scholar
S.-J. Lee, H. M. Lee, S.-T. Ji, S.-R. Lee, W. Mar, and Y. S. Gho, “1,2,3,4,6-Penta-O-galloyl-beta-D-glucose blocks endothelial cell growth and tube formation through inhibition of VEGF binding to VEGF receptor,” Cancer Letters, vol. 208, no. 1, pp. 89–94, 2004.
View at: Publisher Site | Google Scholar
G. Tobelem, “Endothelial cell growth: biology and pharmacology in relation to angiogenesis,” Blood Coagulation & Fibrinolysis, vol. 1, no. 6, pp. 703–705, 1990.
View at: Google Scholar
S. De Falco, “Antiangiogenesis therapy: an update after the first decade,” Korean Journal of Internal Medicine, vol. 29, no. 1, pp. 1–11, 2014.
View at: Publisher Site | Google Scholar
U. Takahama, R. Yamauchi, and S. Hirota, “Isolation and characterization of a cyanidin-catechin pigment from adzuki bean (Vigna angularis),” Food Chemistry, vol. 141, no. 1, pp. 282–288, 2013.
View at: Publisher Site | Google Scholar
N. Ferrara and T. Davis-Smyth, “The biology of vascular endothelial growth factor,” Endocrine Reviews, vol. 18, no. 1, pp. 4–25, 1997.
View at: Publisher Site | Google Scholar
B. Sitohy, J. A. Nagy, and H. F. Dvorak, “Anti-VEGF/VEGFR therapy for cancer: reassessing the target,” Cancer Research, vol. 72, no. 8, pp. 1909–1914, 2012.
View at: Publisher Site | Google Scholar
M. Kowanetz and N. Ferrara, “Vascular endothelial growth factor signaling pathways: therapeutic perspective,” Clinical Cancer Research, vol. 12, no. 17, pp. 5018–5022, 2006.
View at: Publisher Site | Google Scholar
A. Jozkowicz, A. Nigisch, B. Winter, G. Weigel, I. Hukb, and J. Dulaka, “15-deoxy-delta12,14-prostaglandin-J2 inhibits expression of eNOS in human endothelial cells,” Prostaglandins & Other Lipid Mediators, vol. 74, no. 1–4, pp. 11–28, 2004.
View at: Google Scholar
J. Kroll and J. Waltenberger, “VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR),” Biochemical and Biophysical Research Communications, vol. 252, no. 3, pp. 743–746, 1998.
View at: Publisher Site | Google Scholar
Z.-Z. Zheng and Z.-X. Liu, “Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates CD151-induced endothelial cell proliferation and cell migration,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 2, pp. 340–348, 2007.
View at: Publisher Site | Google Scholar
J. Ma, H. Sawai, N. Ochi et al., “PTEN regulate angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells,” Molecular and Cellular Biochemistry, vol. 331, no. 1-2, pp. 161–171, 2009.
View at: Publisher Site | Google Scholar
W. Liu, S. A. Ahmad, N. Reinmuth et al., “Endothelial cell survival and apoptosis in the tumor vasculature,” Apoptosis, vol. 5, no. 4, pp. 323–328, 2000.
View at: Publisher Site | Google Scholar
A. Franovic, C. E. Holterman, J. Payette, and S. Lee, “Human cancers converge at the HIF-2α oncogenic axis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 50, pp. 21306–21311, 2009.
View at: Publisher Site | Google Scholar
H. Wang, K. Y. Cai, W. Li, and H. Huang, “Sphingosine-1-phosphate induces the migration and angiogenesis of EPCs through the Akt signaling pathway via sphingosine-1-phosphate receptor 3/platelet-derived growth factor receptor-beta,” Cellular and Molecular Biology Letters, 2015.
View at: Publisher Site | Google Scholar
M. C. Chen, W. L. Hsu, P. A. Hwang, and T. C. Chou, “Low molecular weight fucoidan inhibits tumor angiogenesis through downregulation of HIF-1/VEGF signaling under hypoxia,” Marine Drugs, vol. 13, no. 7, pp. 4436–4451, 2015.
View at: Publisher Site | Google Scholar
Y. Cao and Q. Lyu, “Epidermal growth factor-like domain 7 promotes endothelial cell migration and angiogenesis by activating ERK signaling pathway,” Zhonghua Bing Li Xue Za Zhi, vol. 44, no. 4, pp. 270–273, 2015.
View at: Google Scholar
S.-J. Lee, S. Namkoong, Y.-M. Kim et al., “Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 291, no. 6, pp. H2836–H2846, 2006.
View at: Publisher Site | Google Scholar
T. Kaneta, T. Kakimoto, and H. Shibaoka, “Gibberellin A₃ causes a decrease in the accumulation of mRNA for ACC oxidase and in the activity of the enzyme in azuki bean (Vigna angularis) epicotyls,” Plant and Cell Physiology, vol. 38, no. 10, pp. 1135–1141, 1997.
View at: Publisher Site | Google Scholar
S.-H. Park, M. Nakajima, M. Sakane, Z.-J. Xu, K. Tomioka, and I. Yamaguchi, “Gibberellin 2-oxidases from seedlings of adzuki bean (Vigna angularis) show high gibberellin-binding activity in the presence of 2-oxoglutarate and Co²⁺,” Bioscience, Biotechnology and Biochemistry, vol. 69, no. 8, pp. 1498–1507, 2005.
View at: Publisher Site | Google Scholar
E. Yanase, K. Nishimoto, Y. O. Kamatari, and S.-I. Nakatsuka, “Isolation of a new xanthylium-related pigment from adzuki beans Vigna angularis,” Bioscience, Biotechnology and Biochemistry, vol. 76, no. 8, pp. 1571–1572, 2012.
View at: Publisher Site | Google Scholar
M.-K. Kang, S. S. Lim, J.-Y. Lee, K. M. Yeo, and Y.-H. Kang, “Anthocyanin-rich purple corn extract inhibit diabetes-associated glomerular angiogenesis,” PLoS ONE, vol. 8, no. 11, Article ID e79823, 2013.
View at: Publisher Site | Google Scholar
K. Matsubara, T. Kaneyuki, T. Miyake, and M. Mori, “Antiangiogenic activity of nasunin, an antioxidant anthocyanin, in eggplant peels,” Journal of Agricultural and Food Chemistry, vol. 53, no. 16, pp. 6272–6275, 2005.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2015 Oh Sung Kwon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1558

Downloads

1140

Citations